{
    "clinical_study": {
        "@rank": "153282", 
        "brief_summary": {
            "textblock": "RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells\n      and slow the growth of glioblastoma multiforme.\n\n      PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have\n      glioblastoma multiforme in first relapse."
        }, 
        "brief_title": "ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse", 
        "completion_date": {
            "#text": "April 2005", 
            "@type": "Actual"
        }, 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Glioblastoma", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the activity of ZD 1839 in patients with glioblastoma multiforme in first\n           relapse.\n\n        -  Determine the pharmacokinetics and toxicity of this drug in these patients.\n\n        -  Assess the relationship between epidermal growth factor receptor status in these\n           patients and activity of this drug.\n\n      OUTLINE: Patients receive oral ZD 1839 once daily. Courses repeat every 28 days in the\n      absence of disease progression or unacceptable toxicity.\n\n      Patients are followed for at least 6 months.\n\n      PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study within 12-18\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed glioblastoma multiforme in first relapse\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 12 weeks\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n\n          -  AST/ALT no greater than 2.5 times ULN\n\n        Renal:\n\n          -  Creatinine less than 1.5 times ULN\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n        Other:\n\n          -  No other uncontrolled concurrent illness\n\n          -  No ongoing or active infection\n\n          -  No psychiatric illness or social situation that would preclude study compliance\n\n          -  No prior allergic reactions to compounds of similar chemical or biologic composition\n             to ZD 1839\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  Ocular inflammation must be fully treated before study entry\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n        Endocrine therapy:\n\n          -  Must be on stable dose of steroids for at least 1 week\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  At least 1 week since prior surgery\n\n        Other:\n\n          -  No other concurrent investigational agents\n\n          -  No other concurrent anticancer therapy\n\n          -  No concurrent combination antiretroviral therapy for HIV\n\n          -  No concurrent enzyme-inducing anticonvulsant drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00016991", 
            "org_study_id": "2421", 
            "secondary_id": [
                "DUMC-2421-03-2R2", 
                "DUMC-2421-01-2", 
                "NCI-1253", 
                "CDR0000068639"
            ]
        }, 
        "intervention": {
            "intervention_name": "gefitinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "keyword": [
            "recurrent adult brain tumor", 
            "adult glioblastoma", 
            "adult giant cell glioblastoma", 
            "adult gliosarcoma"
        ], 
        "lastchanged_date": "June 19, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DUMC-2421-03-2R2"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Henry S. Friedman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00016991"
        }, 
        "responsible_party": {
            "name_title": "Henry Friedman, MD", 
            "organization": "Duke UMC"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2009"
    }, 
    "geocoordinates": {
        "Duke Comprehensive Cancer Center": "35.994 -78.899"
    }
}